<document page-count="7">
<page number="1">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="1" data-table="1"><tr><td colspan="2">Archives of the Balkan Medical Union</td><td>vol. 54, no. 2, pp. 281-287</td></tr><tr><td colspan="2">Copyright © 2019 Balkan Medical Union</td><td>June 2019</td></tr><tr><td></td><td></td><td>ORIGINAL PAPER</td></tr><tr><td colspan="3">THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS</td></tr><tr><td colspan="3">WITH LUNG CANCER ADDRESSED TO A ROMANIAN</td></tr><tr><td colspan="2">TERTIARY PNEUMOLOGY SERVICE</td><td></td></tr><tr><td colspan="2">Bianca PARASCHIV1,2 , Camelia C. DIACONU 1,3</td><td>, Alina CUCU4 , Miron A. BOGDAN 1,4 ,</td></tr><tr><td colspan="2">Claudia L. TOMA 1,4</td><td></td></tr><tr><td style="text-align: right">1</td><td colspan="2">University of Medicine and Pharmacy “Carol Davila“, Bucharest, Romania</td></tr><tr><td style="text-align: right">2</td><td>„Sfantul Stefan“ Hospital, Bucharest, Romania</td><td></td></tr><tr><td style="text-align: right">3</td><td colspan="2">Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest, Bucharest, Romania</td></tr><tr><td style="text-align: right">4</td><td colspan="2">„Marius Nasta“ National Institute of Pneumology, Bucharest, Romania</td></tr><tr><td></td><td></td><td>Received 03 Apr 2019, Accepted 15 May 2019</td></tr><tr><td></td><td></td><td>https://doi.org/10.31688/ABMU.2019.54.2.09</td></tr><tr><td colspan="2">A BSTRACT</td><td>R ÉSUMÉ</td></tr><tr><td colspan="2">Introduction. The lung cancer has an increased in-</td><td>L’évolution des caractéristiques épidémiologiques</td></tr><tr><td colspan="2">cidence and is associated with the highest death by</td><td>chez des patients atteints d’un cancer du poumon</td></tr><tr><td colspan="2">cancer worldwide. It represents a heterogenous disease</td><td>traités dans un centre roumain de spécialité</td></tr><tr><td colspan="2">with variability in trends and has a severe socio-eco-</td><td></td></tr><tr><td colspan="2">nomical impact. That is why it should be continuously</td><td>Introduction. Le cancer du poumon a une incidence</td></tr><tr><td colspan="2">monitored, especially in countries without national</td><td>accrue et il est associé au plus grand nombre de décès</td></tr><tr><td colspan="2">registries or screening programs.</td><td>par cancer dans le monde. Il représente une maladie</td></tr><tr><td colspan="2">The objective of the study was to identify the epi-</td><td>hétérogène dont les tendances varient et a donc un im-</td></tr><tr><td colspan="2">demiological trend in patients with lung cancer ad-</td><td>pact socio-économique grave. C’est pourquoi il devrait</td></tr><tr><td colspan="2">dressed to a Romanian tertiary pneumology service.</td><td>être continuellement surveillé, en particulier dans les</td></tr><tr><td colspan="2">Material and methods. We performed a retrospec-</td><td>pays sans programme national de registre ou de dé-</td></tr><tr><td colspan="2">tive study on 660 patients diagnosed with lung can-</td><td>pistage.</td></tr><tr><td colspan="2">cer: the first group of 260 patients diagnosed between</td><td>L’objectif de l’étudea été d’identifier la tendance</td></tr><tr><td colspan="2">2001-2004, and the second group of 400 patients diag-</td><td>épidémiologique chez les patients atteints de cancer</td></tr><tr><td colspan="2">nosed between 2009-2010.</td><td>du poumon dans notre clinique.</td></tr><tr><td colspan="2">Results.Patients from the first group had a mean</td><td>Matériaux et méthodes.Nous avons mené une</td></tr><tr><td colspan="2">age of 61.20±11.14 years. 80.80% of them were men</td><td>étude rétrospective sur 660 patients atteints d’un can-</td></tr><tr><td colspan="2">and 80.76% smokers. The main symptoms were cough</td><td>cer du poumon : un premier groupe de 260 patients</td></tr><tr><td colspan="2">(46.92%) and dyspnea (45%). The most frequent</td><td>diagnostiqués entre 2001-2004 et un second groupe de</td></tr><tr><td colspan="2">histological subtype was squamous cell carcinoma</td><td>400 patients diagnostiqués entre 2009-2010.</td></tr><tr><td>Address for correspondence:</td><td colspan="2">Camelia C. DIACONU</td></tr><tr><td colspan="3">Internal Medicine Clinic, Clinical Emergency Hospital of Bucharest,</td></tr><tr><td colspan="3">Bucharest, Romania</td></tr><tr><td colspan="3">Address: 8, Calea Floreasca Str, Bucharest, Romania</td></tr><tr><td colspan="3">Email drcameliadiaconu@gmail.com</td></tr></table></page>
<page number="2">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="2" data-table="1"><tr><td colspan="6">The trend of epidemiological data in patients with lung cancer addressed to a romanian... – PARASCHIV et al</td></tr><tr><td>(44.13%). Only 35 patients from the first group un-</td><td colspan="5">Résultats. Dans le premier groupe, nous avons ob-</td></tr><tr><td>derwent surgery. In 2004, from 260 patients enrolled,</td><td colspan="5">servé un âge moyen de 61,20±11,14 ans, une incidence</td></tr><tr><td>20 were still alive. In the second group the mean age</td><td colspan="5">élevée chez les hommes (80,80%), dont (80,76%) des</td></tr><tr><td>was 63.97±10.27 years. 79.05% were men and 84.29%</td><td colspan="5">fumeurs, présentant les principaux symptômes: toux</td></tr><tr><td>smokers. The main symptoms were cough (58.12%)</td><td colspan="5">(46,92%) et dyspnée (45%) et stade avancé de la MNT.</td></tr><tr><td>and dyspnea (40.10%). The most frequent histological</td><td colspan="5">Le sous-type histologique principal était le carcinome</td></tr><tr><td>subtype was the squamous cell carcinoma (47.13%).</td><td colspan="5">à cellules squameuses (44,13%). Seulement 35 patients</td></tr><tr><td>Surgery was performed in 65 patients (16.25%) and</td><td colspan="5">ont été opérés. En 2004, sur 260 patients inscrits,</td></tr><tr><td>they had mean survival of 50 months.</td><td colspan="5">20 étaient encore en vie. Dans le deuxième groupe,</td></tr><tr><td>Conclusions. The incidence of lung cancer is increas-</td><td colspan="5">nous avons signalé un âge moyen de 63,97±10,27 ans,</td></tr><tr><td>ing, especially in centers without screening programs.</td><td colspan="5">avec également une incidence élevée chez les hommes</td></tr><tr><td>There is no change in male prevalence over the years.</td><td colspan="5">(79,05%), des fumeurs (84,29%), présentant les princi-</td></tr><tr><td>Despite the fact that, worldwide, adenocarcinoma has</td><td colspan="5">paux symptômes: toux (58,12%) et dyspnée (40,10%) et</td></tr><tr><td>increased incidence, in our study squamous cell carci-</td><td colspan="5">stade avancé de TNM. Le sous-type histologique prin-</td></tr><tr><td>noma was the main histological subtype. The delays</td><td colspan="5">cipal était le carcinome à cellules squameuses (47,13%).</td></tr><tr><td>in diagnosis remain similar. The majority of patients</td><td colspan="5">La chirurgie a été réalisée chez 65 patients (16,25%) et</td></tr><tr><td>are still diagnosed in advanced stages, when curative</td><td colspan="5">leur survie moyenne était de 50 mois.</td></tr><tr><td>treatment cannot be applied.</td><td colspan="5">Conclusions. L’incidence du cancer du poumon aug-</td></tr><tr><td></td><td colspan="5">mente, en particulier dans les centres sans programme</td></tr><tr><td>Keywords: lung cancer, epidemiology, trend, screen-</td><td colspan="5">de dépistage ni accès à un traitement moléculaire. La</td></tr><tr><td>ing.</td><td colspan="5">prévalence masculine n’a pas changé au fil des années.</td></tr><tr><td></td><td colspan="5">En dépit du fait que l’adénocarcinome a augmenté d’in-</td></tr><tr><td>Abbreviations list</td><td colspan="5">cidence dans le monde, dans notre étude, le carcinome</td></tr><tr><td>COPD – chronic obstructive pulmonary disease</td><td colspan="5">à cellules squameuses reste le principal sous-type histo-</td></tr><tr><td>ICD – International Classifications of Diseases</td><td colspan="5">logique. Le délai du diagnostic reste similaire. La ma-</td></tr><tr><td>NSCLC – non-small cell lung cancer</td><td colspan="5">jorité des patients est encore diagnostiquée à un stade</td></tr><tr><td>PA – Pack-years</td><td colspan="5">avancé en l’absence d’un traitement radical.</td></tr><tr><td>SCLC – small cell lung cancer</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>TNM – Tumor-Node-Metastasis</td><td colspan="5">Mots-clés: cancer du poumon, épidémiologie, ten-</td></tr><tr><td>WHO – World Health Organisation</td><td colspan="2">dance, screening.</td><td></td><td></td><td></td></tr><tr><td>I NTRODUCTION</td><td colspan="5">Lung cancer represents a heterogenous disease,</td></tr><tr><td></td><td colspan="5">with variability in trends, and has a severe socio-eco-</td></tr><tr><td>Starting from 1840, when there were reported</td><td colspan="5">nomical impact. The identification of epidemiological</td></tr><tr><td>only 22 cases in the past 100 years, the lung cancer</td><td colspan="5">features in one region may bring benefits in survival,</td></tr><tr><td>has changed from a rare disease into a global prob-</td><td colspan="5">by adapting screening programs and treatment 9. That</td></tr><tr><td>lem1,2 . In 2018, there were about 18.1 million of new</td><td colspan="5">is why lung cancer should be continuously monitored</td></tr><tr><td>cases, with 9.6 million deaths due to cancer3 . The</td><td colspan="5">for epidemiological trends, especially in countries</td></tr><tr><td>lung cancer is associated with the highest incidence</td><td colspan="5">without national registries or implemented screening</td></tr><tr><td>of death through cancer worldwide1.</td><td>programs.</td><td></td><td></td><td></td><td></td></tr><tr><td>The incidence and mortality rates vary widely</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>globally2 . The lung cancer incidence in countries</td><td>THEOBJECTIVE</td><td>OF</td><td>THE</td><td>STUDY</td><td>was to identify the</td></tr><tr><td>with a low-medium income represents about 50%</td><td colspan="5">changes in epidemiological features over more than</td></tr><tr><td>from the total new cases1. In Europe, the lung cancer</td><td colspan="5">a decade in patients with lung cancer treated in our</td></tr><tr><td>exceeded breast cancer mortality rates for the first</td><td>clinic.</td><td></td><td></td><td></td><td></td></tr><tr><td>time in 20174 . The main incidence of lung cancer</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>in Europe was reported in Central and Eastern</td><td>M ATERIAL</td><td colspan="3">AND METHODS</td><td></td></tr><tr><td>regions 5 . The most important risk factor remains</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>tobacco smoking. Other risk factors are: advanced</td><td colspan="5">We performed a retrospective study on 660</td></tr><tr><td>age, race, sex (male), occupational exposure (mainly</td><td colspan="5">patients diagnosed in the 4 thDepartment of the</td></tr><tr><td>radon exposure), pre-existing diseases (chronic ob-</td><td colspan="5">“Marius Nasta“ National Institute of Pneumology,</td></tr><tr><td>structive pulmonary disease – COPD, tuberculosis),</td><td colspan="5">Bucharest, Romania with lung cancer, defined as</td></tr><tr><td>genetic susceptibility (alteration on chromosome:</td><td colspan="5">ICD 10 codes C34. The patients were divided in two</td></tr><tr><td>15q24-15q25.1, 5p15.33, 6p21.33 , 13q31.36-8 .</td><td colspan="5">groups: the first group of 260 patients diagnosed</td></tr><tr><td>282 / vol. 54, no. 2</td><td></td><td></td><td></td><td></td><td></td></tr></table></page>
<page number="3">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="3" data-table="1"><tr><td colspan="2"></td><td></td><td colspan="3">Archives of the Balkan Medical Union</td></tr><tr><td colspan="2">between 2001-2004, and the second group of 400 pa-</td><td>R ESULTS</td><td colspan="3"></td></tr><tr><td colspan="2">tients diagnosed between 2009-2010.</td><td></td><td colspan="3"></td></tr><tr><td colspan="2">The information was obtained from the medical</td><td colspan="4">The statistical analysis was performed for each</td></tr><tr><td colspan="2">files of the patients found in the hospital archive. We</td><td colspan="4">group individually. The results were compared and</td></tr><tr><td colspan="2">included all the patients diagnosed with lung cancer.</td><td colspan="4">discussed for each variable separately.</td></tr><tr><td colspan="2">The access to the observation sheets was done based</td><td colspan="4">The first group of patients included 260 sub-</td></tr><tr><td colspan="2">on a previous permission granted by the hospital man-</td><td colspan="4">jects. We observed a constant increase in the inci-</td></tr><tr><td colspan="2">agement. On admission, each patient consented that</td><td colspan="4">dence of lung cancer over the years (Figure 1). The</td></tr><tr><td colspan="2">his medical information may be used for research pur-</td><td colspan="4">general characteristics of the group are resumed in</td></tr><tr><td colspan="2">poses.</td><td colspan="4">Table 1. About 56% of the patients accused symp-</td></tr><tr><td colspan="2">The statistical interpretation of data included a</td><td colspan="4">toms with at least 2 months before presentation for</td></tr><tr><td colspan="2">descriptive analysis carried out in the form of Medium</td><td colspan="4">medical examination. The main clinical features were</td></tr><tr><td colspan="2">± Standard Deviation (SD) and minimum and maxi-</td><td colspan="4">cough (46.92%) and dyspnea (45%). Only 6% of pa-</td></tr><tr><td colspan="2">mum for the continuous variables, and in the form of</td><td colspan="4">tients were asymptomatic and diagnosed on a rou-</td></tr><tr><td colspan="2">absolute frequencies (number) and relative frequencies</td><td colspan="4">tinely performed chest X-ray (Table 2). The mean age</td></tr><tr><td colspan="2">(percentage) for the category variables; the survival</td><td colspan="4">at the time of diagnosis was around 60 years old, with</td></tr><tr><td colspan="2">was investigated with Kaplan-Meyer analysis.</td><td colspan="4">33% of patients aged between 55-64 years old. The</td></tr><tr><td></td><td colspan="2">Table 1. General characteristics of the groups of study.</td><td></td><td></td><td></td></tr><tr><td>Variable</td><td></td><td>Group 1</td><td>Group 2</td><td></td><td></td></tr><tr><td>Age – Average ± D.S</td><td></td><td style="text-align: right">61.20 ± 11.14</td><td style="text-align: right">63.97 ± 10.27</td><td></td><td></td></tr><tr><td></td><td>M</td><td style="text-align: right">209 (80.08%)</td><td style="text-align: right">317 (79.05%)</td><td></td><td></td></tr><tr><td>Sex</td><td>F</td><td style="text-align: right">51 (19.92%)</td><td style="text-align: right">84 (20.95%)</td><td></td><td></td></tr><tr><td></td><td>Yes</td><td style="text-align: right">210 (80.76%)</td><td style="text-align: right">338 (84.29%)</td><td></td><td></td></tr><tr><td>Smokers</td><td>No</td><td style="text-align: right">50 (19.23%)</td><td style="text-align: right">63 (15.71%)</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">1</td><td style="text-align: right">10 (4.03%)</td><td style="text-align: right">19 (5.29%)</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">2</td><td style="text-align: right">16 (6.15%)</td><td style="text-align: right">22 (6.13%)</td><td></td><td></td></tr><tr><td>TNM stage</td><td style="text-align: right">3</td><td style="text-align: right">98 (37.69%)</td><td style="text-align: right">124 (34.54%)</td><td></td><td></td></tr><tr><td></td><td style="text-align: right">4</td><td style="text-align: right">136 (52.13%)</td><td style="text-align: right">194 (54.04%)</td><td></td><td></td></tr><tr><td></td><td>Squamous</td><td style="text-align: right">109 (44.13%)</td><td style="text-align: right">123 (47.13%)</td><td></td><td></td></tr><tr><td></td><td>ADK</td><td style="text-align: right">91 (36.84%)</td><td style="text-align: right">98 (37.55%)</td><td></td><td></td></tr><tr><td>Histology</td><td>Others</td><td style="text-align: right">18 (7.29%)</td><td style="text-align: right">6 (2.30%)</td><td></td><td></td></tr><tr><td></td><td>SCLC</td><td style="text-align: right">29 (11.74%)</td><td style="text-align: right">34 (13.03%)</td><td></td><td></td></tr><tr><td></td><td colspan="3">Figure 1. The increasing incidence of lung cancer in our clinic between 2001-2004.</td><td></td><td></td></tr><tr><td></td><td></td><td></td><td>June 2019</td><td style="text-align: right">/</td><td style="text-align: right">283</td></tr></table></page>
<page number="4">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="4" data-table="1"><tr><td colspan="4">The trend of epidemiological data in patients with lung cancer addressed to a romanian... – PARASCHIV et al</td></tr><tr><td></td><td colspan="2">Table 2. Clinical features of the groups of study</td><td></td></tr><tr><td>Variable</td><td></td><td>Group 1</td><td>Group 2</td></tr><tr><td>Asymptomatic (N = 249)</td><td>Yes<br/>No</td><td>15 (5.77%)<br/>245 (94.23%)</td><td>25 (10.04%)<br/>224 (89.96%)</td></tr><tr><td>Dyspnea</td><td>Yes<br/>No</td><td>117 (45%)<br/>143 (55%)</td><td>158 (40.10%)<br/>236 (59.90%)</td></tr><tr><td>Cough</td><td>Yes<br/>No</td><td>122 (46.92%)<br/>138 (53.08%)</td><td>229 (58.12%)<br/>165 (41.88%)</td></tr><tr><td>Fatigue</td><td>Yes<br/>No</td><td>65 (25%)<br/>195 (75%)</td><td>120 (30.53%)<br/>273 (69.47%)</td></tr><tr><td>Chest paint</td><td>Yes<br/>No</td><td>70 (26.92%)<br/>190 (70.08%)</td><td>128 (32.57%)<br/>265 (67.43%)</td></tr><tr><td>Hemoptysis</td><td>Yes<br/>No</td><td>75 (28.85%)<br/>185 (71.15%)</td><td>92 (23.41%)<br/>301 (76.59%)</td></tr><tr><td>Dysphonia</td><td>Yes<br/>No</td><td>14 (5.39%)<br/>246 (94.61%)</td><td>18 (4.58%)<br/>375 (95.42%)</td></tr><tr><td>Dysphagia</td><td>Yes<br/>No</td><td>13 (5%)<br/>247 (95%)</td><td>9 (2.28%)<br/>385 (97.72%)</td></tr><tr><td>Superior Vena Cava syndrome</td><td>YNeos</td><td style="text-align: right">2573 ( (29.67.93%1)%)</td><td style="text-align: right">3868  ((19.58.24%8)%)</td></tr><tr><td colspan="3">Figure 2. The general survival in the second group of study.</td><td></td></tr><tr><td colspan="2">majority of patients were male (80.80%) and heavy</td><td colspan="2">with stage II, 11 patients in stage III A, 2 patients</td></tr><tr><td colspan="2">smokers (80.76%). The main comorbidities were car-<br/>diovascular diseases (12%) and chronic obstructive<br/>pulmonary disease (13%). The main histological sub-</td><td colspan="2">in stage IIIB, 4 patients in stage IV (patients with<br/>unique metastases and resectable primary tumor).<br/>The types of surgery excisions were: lobectomy (the</td></tr><tr><td colspan="2">type was squamous cell carcinoma (44.13%). Most</td><td colspan="2">most frequent), bi-lobectomy, pneumectomy. None</td></tr><tr><td colspan="2">patients presented with advanced disease: 89.91%</td><td colspan="2">of these 35 patients underwent neo-adjuvant chemo-</td></tr><tr><td colspan="2">in stage III and IV. Treatment with intent to cure</td><td colspan="2">therapy. In 2004, from 260 patients enrolled, 20 were</td></tr><tr><td colspan="2">was proposed to 50 patients, but only 35 patients un-</td><td colspan="2">still alive. From those 20 patients, 15 benefited from</td></tr><tr><td colspan="2">derwent surgery: 8 patients with stage I, 10 patients</td><td colspan="2">surgical treatment.</td></tr><tr><td colspan="2">284 / vol. 54, no. 2</td><td colspan="2"></td></tr></table></page>
<page number="5">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="5" data-table="1"><tr><td></td><td>Archives of the Balkan Medical Union</td></tr><tr><td>In the second group, there were included 400</td><td>published, according to which the global incidence</td></tr><tr><td>patients, with a mean age of approx. 60 years old</td><td>of cancer is constantly increasing1.</td></tr><tr><td>also. The main features are presented in Table 1. We</td><td>Age was a frequent analyzed feature. Some</td></tr><tr><td>observed a male prevalence (79.05%). The majority</td><td>studies stipulated that an advanced age (over 65 yo</td></tr><tr><td>of patients were smokers (84.29%) with an average</td><td>in some reports, or over 70 yo) is associated with a</td></tr><tr><td>packs-year of 42.86±20.25. Only 21.30% of them</td><td>worse prognosis, but other studies did not confirm</td></tr><tr><td>had professional exposure. About 5.99% of patients</td><td>it13 . Nevertheless, most cases of lung cancer are diag-</td></tr><tr><td>had a family history of lung cancer. The main co-</td><td>nosed in patients between 55-74 years old, that is why</td></tr><tr><td>morbidities were cardiovascular diseases. The most</td><td>it is difficult to establish the age impact on survival 2 .</td></tr><tr><td>prevalent clinical features were cough (58.12%) and</td><td>In our study, we encountered a mean age of about 60</td></tr><tr><td>dyspnea (40.10%). The main histological type was</td><td>years old in both groups (61.20±11.14 vs 63.97±10.27).</td></tr><tr><td>the non-small cell lung cancer (NSCLC), represented</td><td>We observed that over a decade there was no signifi-</td></tr><tr><td>mainly by squamous cell carcinoma (47.13%) and ad-</td><td>cant change of this parameter. Our results confirm</td></tr><tr><td>enocarcinoma (37.55%). Approximately 88.58% of pa-</td><td>the ones published in other studies.</td></tr><tr><td>tients were diagnosed in advanced stages. Surgery was</td><td>In the last years, many epidemiological studies</td></tr><tr><td>performed in 65 patients (16.25%). The main tech-</td><td>observed a decrease in the incidence among men and</td></tr><tr><td>niques were lobectomy and wedge resection. In the</td><td>an increase among women 2 . The highest incidence in</td></tr><tr><td>group of patients who underwent surgery, the progno-</td><td>women was reported in North America and Northern</td></tr><tr><td>sis was better: they had a mean survival of 50 months</td><td>Europe10 . These changes may be influenced also by</td></tr><tr><td>vs. a mean survival of approximately 17 months in</td><td>smoking habits and by genetic alteration, such as</td></tr><tr><td>patients in whom the radical surgery was not possible</td><td>over-expression of the CYP1A1 gene or of X-linked</td></tr><tr><td>(p&lt;0.01). Most patients were treated with chemother-</td><td>gastrin-releasing peptide receptor and mutation of</td></tr><tr><td>apy in an external oncology service. In patients who</td><td>the glutathione S-transferase M1 enzyme or of the</td></tr><tr><td></td><td style="text-align: right">(14)</td></tr><tr><td>were not candidates for surgical procedures and were</td><td>p53 tumor suppressor gene  . Nevertheless, the in-</td></tr><tr><td>treated with chemotherapy the mean survival was 6</td><td>cidence in men remains higher than in women1 . In</td></tr><tr><td>months longer in the group with chemotherapy.</td><td>our study, we observed the same results: a high inci-</td></tr><tr><td></td><td>dence in male, which was preserved over the years:</td></tr><tr><td></td><td>209 (80.08%) vs 317 (79.05%).</td></tr><tr><td>D ISCUSSION</td><td>Some researchers have argued that the African</td></tr><tr><td></td><td>race is a negative prognostic factor15 . However, after</td></tr><tr><td>Only about one si1x0 th of the countries worldwide</td><td>adjusting the results with socio-cultural differences (ac-</td></tr><tr><td>have cancer registries. In Romania, there is not a</td><td>cess to medical services, smoker status, diet, sedentary</td></tr><tr><td>national registry of lung cancer. One of the purposes</td><td>lifestyle), the influence of race on the evolution of lung</td></tr><tr><td>of these registries is to identify the risk factors based</td><td>cancer fades away2,16 . In our group, we could not assess</td></tr><tr><td>on epidemiological features for each geographic re-</td><td>race differences because all patients were Caucasians.</td></tr><tr><td>gion, in order to implement custom made screening</td><td>Smoking as risk factor for lung cancer has been</td></tr><tr><td>programs. Given that survival in lung cancer dramati-</td><td>recognized since 1960. About 80% of lung cancers</td></tr><tr><td>cally decreases with disease progression, the early di-</td><td>are linked to tobacco smoking 6 . Both the duration</td></tr><tr><td>agnosis remains essential11. That is why the screening</td><td></td></tr><tr><td></td><td>and the number of cigarettes per day are independent</td></tr><tr><td>programs play a key-role in survival. In Europe, the</td><td>risk factors. Knowing the high incidence of smoking</td></tr><tr><td>screening is performed yearly by low-dose computed</td><td>between lung cancer patients, an active and constant</td></tr><tr><td>tomography scans in patients at risk (55-80 years old,</td><td>fight for its cessation can make the difference. For</td></tr><tr><td>smokers or ex-smokers secluded for a maximum of</td><td>example, in the USA, the age-adjusted incidence has</td></tr><tr><td>15 years, with a history of at least 30 PA, with one</td><td>declined due to changes in risk behaviors secondary</td></tr><tr><td>additional risk factor – personal history of cancer/</td><td>to promulgation of information about the main risk</td></tr><tr><td>COPD/ pulmonary fibrosis/ occupational exposure</td><td>factor: tobacco smoking 2 . In our country, only a few</td></tr><tr><td>or family history of lung cancer) only in specialized</td><td>years ago a law prohibiting smoking in closed spaces</td></tr><tr><td>medical centers12 . In Romania, there are no screen-</td><td>was promulgated, so smoking remains a main risk</td></tr><tr><td>ing programs implemented, so all the data regarding</td><td>factor for the population included in our study. There</td></tr><tr><td>lung cancer come from different studies performed</td><td>are no differences between smoking incidence over</td></tr><tr><td>in several clinics.</td><td>the years: 210 (80.76%) vs 338 (84.29%). The high</td></tr><tr><td>The first variable analyzed was the evolution of</td><td>incidence of tobacco use correlates with the results</td></tr><tr><td>incidence over the years. Our data confirm that there</td><td>reported by other studies.</td></tr><tr><td>is a significant increase of lung cases reports since</td><td>In 2015, the World Health Organization (WHO)</td></tr><tr><td>2001 until 2010. The results confirm the reports</td><td>published the latest histopathological classification</td></tr><tr><td></td><td>June 2019 / 285</td></tr></table></page>
<page number="6">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="6" data-table="1"><tr><td colspan="4">The trend of epidemiological data in patients with lung cancer addressed to a romanian... – PARASCHIV et al</td></tr><tr><td colspan="2">based on immunohistochemistry and genetics tests</td><td colspan="2">C ONCLUSIONS</td></tr><tr><td colspan="2">and on the degree of differentiation. The NSCLC</td><td></td><td></td></tr><tr><td colspan="2">type has been reported to have the highest preva-</td><td></td><td>Lung cancer is associated with a high mortal-</td></tr><tr><td colspan="2">lence17. Recent studies suggest an increase in the inci-</td><td colspan="2">ity. The prevalence is increasing from few cases in</td></tr><tr><td colspan="2">dence of adenocarcinoma at the expense of squamous</td><td colspan="2">2001 to nearly a hundred new cases in 2009. The</td></tr><tr><td colspan="2">carcinoma18,19. We also identified in our group a prev-</td><td colspan="2">mean age at diagnosis remains around 60 yo24 . There</td></tr><tr><td colspan="2">alence of NSCLC constant over the years: 80.97 vs</td><td colspan="2">is still a male predominant distribution. Smoking</td></tr><tr><td colspan="2">84.68%. However, we did not observe an increase of</td><td colspan="2">incidence is high in our groups, without significant</td></tr><tr><td colspan="2">incidence of adenocarcinoma. In both groups, squa-</td><td colspan="2">decrease over the years as it was reported in other</td></tr><tr><td colspan="2">mous cell carcinoma had a higher prevalence: 44.13%</td><td colspan="2">countries. Squamous cell carcinoma remains the pre-</td></tr><tr><td colspan="2">vs 47.13%. Furthermore, studies reported a higher in-</td><td colspan="2">dominant histopathological subtype over the years.</td></tr><tr><td colspan="2">cidence of adenocarcinoma in male patients2 . Even</td><td colspan="2">Similar delay between symptoms and diagnosis is ob-</td></tr><tr><td colspan="2">though in our study there was a male predominance,</td><td colspan="2">served in both groups. The main clinical symptoms</td></tr><tr><td colspan="2">squamous cell carcinoma remains the most frequent</td><td colspan="2">remain dyspnea and cough. Patients continue to be</td></tr><tr><td colspan="2">histological subtype over the years.</td><td colspan="2">diagnosed in advanced stages25 . Treatment with the</td></tr><tr><td colspan="2">The TNM classification was first described in</td><td colspan="2">intent to cure has a significant benefit for survival.</td></tr><tr><td colspan="2">1942-1952 in France and in 1958 there were published</td><td></td><td>Lung cancer remains a global burden because</td></tr><tr><td colspan="2">the first guidelines. It applies in SCLC and NSCLC,</td><td colspan="2">of the aggressive character of the disease and its con-</td></tr><tr><td colspan="2">including the carcinoid tumors, but not for rare tu-</td><td colspan="2">stantly increasing incidence. Primary prevention,</td></tr><tr><td colspan="2">mors, such as sarcoma. The TNM classification is re-</td><td colspan="2">such as tobacco control, remains a key factor in prog-</td></tr><tr><td colspan="2">peatedly identified as an essential prognostic factor</td><td colspan="2">nosis improvement. Understanding the evolution of</td></tr><tr><td colspan="2">in the progression of lung cancer. In 2017, the eighth</td><td colspan="2">epidemiological features in lung cancer provides the</td></tr><tr><td colspan="2">edition of TNM staging was used 20 . However, the</td><td colspan="2">necessary information for screening programs to be</td></tr><tr><td colspan="2">classification of the patients in our study was based</td><td colspan="2">tailored to populations at highest risk. The imple-</td></tr><tr><td colspan="2">on the staging valid at the time of diagnosis. Despite</td><td colspan="2">mentation of screening programs and national regis-</td></tr><tr><td colspan="2">the TNM edition used, the reports have shown that</td><td colspan="2">tries is essential for improving the survival rate.</td></tr><tr><td colspan="2">the diagnosis is confirmed mainly in advanced stages:</td><td></td><td></td></tr><tr><td colspan="2">only 15% of cases are diagnosed in early stages21. The</td><td></td><td></td></tr><tr><td colspan="2">same results we observed in our study, where despite</td><td colspan="2">Compliance with Ethics Requirements:</td></tr><tr><td colspan="2">a decade of progress the majority of patients are still</td><td></td><td>„The authors declare no conflict of interest regarding</td></tr><tr><td colspan="2">diagnosed in advanced stages, when curative therapy</td><td colspan="2">this article“</td></tr><tr><td colspan="2">is no longer an option: 89.91% vs 88.58%.</td><td></td><td>„The authors declare that all the procedures and ex-</td></tr><tr><td colspan="2">With the progress of surgical procedures and</td><td colspan="2">periments of this study respect the ethical standards in the</td></tr><tr><td colspan="2">discovery of molecular treatment, the survival rate</td><td colspan="2">Helsinki Declaration of 1975, as revised in 2008(5), as</td></tr><tr><td colspan="2">has increased over the years, but lung cancer is still</td><td colspan="2">well as the national law. Informed consent was obtained</td></tr><tr><td colspan="2">associated with highest mortality. The 1-year relative</td><td colspan="2">from all the patients included in the study“</td></tr><tr><td colspan="2">survival rate increased from 35% in 1975-1979 to 42%</td><td></td><td>„No funding for this study“</td></tr><tr><td colspan="2">in 1988-200821. The prognosis is influenced by many</td><td></td><td></td></tr><tr><td colspan="2">factors: patients’ characteristics (clinical status, comor-</td><td></td><td></td></tr><tr><td colspan="2">bidities, age) and tumor characteristics (TNM stage,</td><td colspan="2">R EFERENCES</td></tr><tr><td colspan="2">histopathology, immunohistochemistry)22 . From all</td><td></td><td></td></tr><tr><td colspan="2">these factors, the TNM classification has an important</td><td style="text-align: right">1.</td><td>www.globocan.iac.fr. (accesed 12 March 2019).</td></tr><tr><td colspan="2">role: the survival rate decreases from stage I (where is</td><td style="text-align: right">2.</td><td>de Groot PM, Wu CC, Carter BW, Munden RF. The</td></tr><tr><td></td><td></td><td></td><td>epidemiology of lung cancer. Transl Lung Cancer Res.</td></tr><tr><td colspan="2">estimated at 59 months) to 4 months in stage IV 23 .</td><td></td><td>2018;7(3):220-233.</td></tr><tr><td colspan="2">These observations are sustained by the results of our</td><td style="text-align: right">3.</td><td>World Health Organization. Press release no 263, 12</td></tr><tr><td colspan="2">study. In both groups, the survival was better in early</td><td></td><td>Septembrie 2018. Globocan database. https://www.who.</td></tr><tr><td colspan="2">TNM stages, where surgical resection was performed.</td><td></td><td>int/cancer/PRGlobocanFinal.pdf. (Accessed 01 April 2019).</td></tr><tr><td></td><td></td><td style="text-align: right">4.</td><td>Malvezzi M, Carioli G, Bertuccio P, et al. European cancer</td></tr><tr><td></td><td></td><td></td><td>mortality predictions for the year 2017, with focus on lung</td></tr><tr><td>L IMITATIONS</td><td>OF THE STUDY</td><td></td><td>cancer. Ann Oncol. 2017;28(5):1117-1123.</td></tr><tr><td></td><td></td><td style="text-align: right">5.</td><td>Siegel R, Naishadham D, Jemal A. Cancer statistics. CA</td></tr><tr><td colspan="2">Our research presents some limitations of statis-</td><td></td><td>Cancer J Clin. 2012;62 (1):10–29.</td></tr><tr><td colspan="2">tical analysis, mainly because a retrospective study is</td><td style="text-align: right">6.</td><td>Malhotra J, Malvezzi M, Negri E. Risk factors for lung can-</td></tr><tr><td colspan="2">a source of recall bias. Other limitation come from</td><td></td><td>cer worldwide. Eur Respir J. 2016; 48(3):889-902.</td></tr><tr><td></td><td></td><td style="text-align: right">7.</td><td>Spyratos D, Zarogoulidis P, Porpodis K, et al. Occupational</td></tr><tr><td colspan="2">the incomplete data from the patients’ charts, due to</td><td></td><td>exposure and lung cancer. J Thorac Dis. 2013;5(4):S440–</td></tr><tr><td colspan="2">the lack of national registries.</td><td></td><td>S445.</td></tr><tr><td colspan="2">286 / vol. 54, no. 2</td><td></td><td></td></tr></table></page>
<page number="7">
<table data-filename="09.THE TREND OF EPIDEMIOLOGICAL DATA IN PATIENTS WITH LUNG CANCER.pdf" data-page="7" data-table="1"><tr><td></td><td></td><td>Archives of the Balkan Medical Union</td></tr><tr><td style="text-align: right">8.</td><td>Pallis AG, Syrigos KN. Lung cancer in never smokers:</td><td>16. Patel MI, Wang A, Kapphahn K, et al. Racial and ethnic</td></tr><tr><td></td><td>disease characteristics and risk factors. Crit Rev Oncol</td><td>variations in lung cancer incidence and mortality: results</td></tr><tr><td></td><td>Hematol. 2013; 88(3):494-503.</td><td>from the women’s health initiative. Clin Oncol. 2016;34</td></tr><tr><td style="text-align: right">9.</td><td>Gaga M, Powell CA, Schraufnage DE, et al. An official</td><td>(4):360-368.</td></tr><tr><td></td><td>American Thoracic Society/ European Respiratory Society</td><td>17. Travis D, Brambilla E, Nicholson AG, et al. The 2015 World</td></tr><tr><td></td><td>statement: the role of the pulmonologist in the diagnosis</td><td>Health Organization classification of lung tumors: Impact of</td></tr><tr><td></td><td>and management of lung cancer. Am J Respir Crit Care Med.</td><td>Genteic, Clincal and Radiologic Advances Since the 2004</td></tr><tr><td></td><td>2013;188(4):503–507.</td><td>Classification. J Thorac Oncol. 2015;10(9):1243–1260.</td></tr><tr><td colspan="2">10. Cheng T-YD, Cramb SM, Baade PD. The international epi-</td><td>18. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epi-</td></tr><tr><td></td><td>demiology of lung cancer: latest trends, disparities, and tu-</td><td>demiology, etiology, and prevention. Clin Chest Med. 2011;</td></tr><tr><td></td><td>mor characteristics. J Thorac Oncol. 2016;11(10):1653–1671.</td><td>32(4):605-644.</td></tr><tr><td style="text-align: right">11.</td><td>Field JK, Chen Y, Marcus MW, et al. The contribution of</td><td>19. Paraschiv B, Dediu G, Iancu A, Bratu O, Diaconu C.</td></tr><tr><td></td><td>risk prediction models to early detection of lung cancer. J</td><td>Superior vena cava syndrome – review. Arch Balk Med Union</td></tr><tr><td></td><td>Surg Oncol. 2013;108 (5):304–311.</td><td>2017;52(1):39-43.</td></tr><tr><td colspan="2">12. Kauczor H-U., Bonomo L, Gaga M, et al. ESR/ERS white</td><td>20. Detterbeck FC, Boffa DJ, Kim AW, et al. The eighth edition</td></tr><tr><td></td><td>paper on lung cancer screening. Eur Respir J. 2015;46 (1):28–</td><td>lung cancer stage classification. Chest. 2017;151(1):193-203.</td></tr><tr><td></td><td style="text-align: right">39.</td><td>21. Ridge CA, McErlean AM, Ginsberg MS. Epidemiology of</td></tr><tr><td colspan="2">13. Carter GC, Barrett AM, Kaye JA, et al. A comprehensive</td><td>lung cancer. Semin Intervent Radiol 2013;30 (2):93–98.</td></tr><tr><td></td><td>review of nongenetic prognostic and predictive factors</td><td>22. Ciuhu AN, Rahnea Nita RA, Popescu M, et al. Evidence</td></tr><tr><td></td><td>influencing the heterogeneity of outcomes in advanced</td><td>of strong opioid therapy for palliation of breathlesness in</td></tr><tr><td></td><td>non-small-cell lung cancer. Cancer Management and Research.</td><td>cancer patients. Farmacia 2017;65(2):173-178.</td></tr><tr><td></td><td>2014:6:437–449.</td><td>23. Midthun DE. Overview of the initial evaluation, treatment</td></tr><tr><td colspan="2">14. Kligerman S, White C. Epidemiology of lung cancer in wom-</td><td>and prognosis of lung cancer. www.uptodate. (Accessed</td></tr><tr><td></td><td>en: risk factors, survival, and screening. AJR Am J Roentgenol.</td><td>August 2018).</td></tr><tr><td></td><td>2011;196 (2):287-95.</td><td>24. Diaconu CC, Arsene D, Paraschiv B, Balaceanu A, Bartos</td></tr><tr><td colspan="2">15. Blackstock AW, Herndon JE 2nd, Paskett ED, et al.</td><td>D. Hyponatremic encephalopathy as the initial sign of</td></tr><tr><td></td><td>Outcomes among African-American/non African-American</td><td>neuroendocrine small cell carcinoma – case report. Acta</td></tr><tr><td></td><td>patients with advanced non-small cell lung carcinoma: re-</td><td>Endocrinologica 2013;IX(4): 637-642.</td></tr><tr><td></td><td>port from the Cancer and Leukemia Group B. J Natl Cancer</td><td>25. Paraschiv B, Diaconu C, Toma C, Bogdan M. Paraneoplastic</td></tr><tr><td></td><td>Inst. 2002;94:284.</td><td>syndromes: the way to an early diagnosis of lung cancer.</td></tr><tr><td></td><td></td><td>Pneumologia 2015;64(2):14-19.</td></tr><tr><td></td><td></td><td>June 2019 / 287</td></tr></table></page>
</document>
